Ann: Results of BARD1 Ovarian Cancer Study, page-116

in regards to how much could potentially be made from testing OVARIAN CANCER TESTING A MULTI-BILLION BUSINESS

Ovarian cancer is the leading cause of gynaecological cancer deaths and seventh most common cancer in women worldwide, with around 239,000 new cases diagnosed and 152,000 deaths in 2012.3 Ovarian cancer is often diagnosed at a late stage after symptoms have appeared, resulting in a poor prognosis with an overall 5-year survival rate of 46% in the US, and recurrence of around 70% after 12-18 months. Earlier detection by finding ovarian cancer when local rather than distant may increase 5-year survival from 29% to 92%, a potential survival improvement of 3 times. There is a clear unmet clinical need for non-invasive, accurate and affordable diagnostic tests for the early detection and monitoring of ovarian cancer. The global ovarian cancer diagnostics market was valued at US$7.2B in 2013 and is expected to grow at 7.2% annually to reach US $11.8B by 20204.